Galderma reported FY 2025 net sales of USD 5.207 billion, up 18.1%, and Q4 2025 net sales of USD 1.469 billion, up 27.6%. FY 2025 operating profit was USD 829 million and net income was USD 613 million. FY 2025 Core EBITDA was USD 1.211 billion with a 23.3% margin, while Core net income was USD 871 million and Core EPS was USD 3.69 (up 76.7%). Total net indebtedness was USD 1.822 billion at December 31, 2025. By segment in FY 2025, Injectable Aesthetics sales were USD 2.572 billion (up 11.9%), Dermatological Skincare USD 1.449 billion (up 8.9%), and Therapeutic Dermatology USD 1.185 billion (up 52.0%). Nemluvio delivered FY 2025 net sales of USD 452 million, more than 19x higher than the prior year, and Q4 2025 Nemluvio sales were USD 188 million, more than 8x higher. Business highlights included Relfydess launches in 17 International markets and approval in 23 International markets, with the FDA accepting a resubmitted BLA on February 2, 2026. Sculptra gained share in its first year in China and received EU MDR certification expanding use beyond the face. In Fillers, the FDA approved Restylane Lyft with Lidocaine in November 2025 for chin augmentation. The company guided for FY 2026 net sales growth of 17%–20% at constant currency and a Core EBITDA margin of approximately 26% at constant currency, and raised Nemluvio peak sales guidance to above USD 4 billion. Galderma also proposed a CHF 0.35 per share dividend and noted L’Oréal increased its stake to 20% (closed February 2026).
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galderma Group AG published the original content used to generate this news brief via Business Wire (Ref. ID: 202603050100BIZWIRE_USPR_____20260304_BW261230) on March 05, 2026, and is solely responsible for the information contained therein.